DK0996717T3 - Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination - Google Patents

Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination

Info

Publication number
DK0996717T3
DK0996717T3 DK98946321T DK98946321T DK0996717T3 DK 0996717 T3 DK0996717 T3 DK 0996717T3 DK 98946321 T DK98946321 T DK 98946321T DK 98946321 T DK98946321 T DK 98946321T DK 0996717 T3 DK0996717 T3 DK 0996717T3
Authority
DK
Denmark
Prior art keywords
antigen
vaccination
influenza antigen
influenza
relates
Prior art date
Application number
DK98946321T
Other languages
Danish (da)
English (en)
Inventor
Walter Fiers
Sabine Neirynck
Jou Willy Min
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0996717(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of DK0996717T3 publication Critical patent/DK0996717T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98946321T 1997-08-05 1998-08-05 Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination DK0996717T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97202434 1997-08-05

Publications (1)

Publication Number Publication Date
DK0996717T3 true DK0996717T3 (da) 2006-04-10

Family

ID=8228624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98946321T DK0996717T3 (da) 1997-08-05 1998-08-05 Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination

Country Status (10)

Country Link
US (1) US7732130B2 (https=)
EP (1) EP0996717B1 (https=)
JP (2) JP5132851B2 (https=)
AT (1) ATE312172T1 (https=)
AU (1) AU745951B2 (https=)
CA (1) CA2297786C (https=)
DE (1) DE69832706T2 (https=)
DK (1) DK0996717T3 (https=)
ES (1) ES2255181T3 (https=)
WO (1) WO1999007839A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
HK1052949B (en) * 2000-04-14 2011-04-29 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
WO2001083528A2 (en) * 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
KR20040111402A (ko) * 2002-03-13 2004-12-31 기린 비루 가부시키가이샤 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
NZ542935A (en) * 2003-04-23 2008-08-29 Wisconsin Alumni Res Found Recombinant influenza viruses holding a mutation in a transmembrane protein gene
CA2530363C (en) * 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
EP1819732A2 (en) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
WO2007066334A1 (en) 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
RU2009105099A (ru) 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
KR20090096414A (ko) 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
DK2069503T3 (da) * 2006-11-15 2016-02-15 Folia Biotech Inc Papayamosaikvirus-baserede vacciner mod influenza
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EP2173376B1 (en) 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
CA2742288A1 (en) * 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
CN102549152B (zh) * 2009-07-31 2015-11-25 帕克斯瓦克斯股份有限公司 基于腺病毒的载体
CN102612559B (zh) 2009-08-28 2015-06-10 一般财团法人化学及血清疗法研究所 源自流感m2的修饰的肽疫苗
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CA3014435C (en) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Improved influenza b virus replication for vaccine development
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919044A (en) 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
WO1992022575A1 (en) * 1991-06-19 1992-12-23 Sri International M-protein peptides of influenza virus as antiviral agents
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
AU687805B2 (en) * 1993-04-27 1998-03-05 United Biomedical Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ATE215124T1 (de) * 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US20020015951A1 (en) 2000-01-06 2002-02-07 Bader Joel S. Method of analyzing a nucleic acid

Also Published As

Publication number Publication date
ATE312172T1 (de) 2005-12-15
WO1999007839A2 (en) 1999-02-18
ES2255181T3 (es) 2006-06-16
CA2297786A1 (en) 1999-02-18
EP0996717A2 (en) 2000-05-03
JP5132851B2 (ja) 2013-01-30
EP0996717B1 (en) 2005-12-07
US7732130B2 (en) 2010-06-08
DE69832706T2 (de) 2006-08-10
AU745951B2 (en) 2002-04-11
US20060246092A1 (en) 2006-11-02
CA2297786C (en) 2011-06-14
JP2010059164A (ja) 2010-03-18
DE69832706D1 (de) 2006-01-12
AU9341698A (en) 1999-03-01
JP2001512748A (ja) 2001-08-28
WO1999007839A3 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
DK0996717T3 (da) Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
DK1032374T3 (da) Sphroider, fremgangsmåde og farmaceutiske præparater
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
DE60331224D1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
DE69836976D1 (de) Neospora impstoff
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
HUP9802238A2 (hu) Fokozott immunizáló képességű módosított polipeptidek
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2004003009A3 (en) Francisella tularensis immunogenic proteins and dna encoding these
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
DK1158050T3 (da) Human cysteinyl-leukotrienreceptor (CysLT2)